LEXINGTON, Mass. -- (BUSINESS WIRE) -- Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced the appointment of Pierre Cassigneul as the company’s new chief executive officer. Mr. Cassigneul is a seasoned executive with more than 25 years of commercial experience in the healthcare and molecular diagnostic industries. He brings significant international and product commercialization experience to Predictive Biosciences, having held top management positions at several leading global diagnostics companies. Mr. Cassigneul replaces Marc Schneebaum, who will return to his original role as chief operating officer.
“I am very excited to be joining the company at this important inflection point in its commercial growth and look forward to working with such a remarkable team, both in vision and scientific excellence,” said Pierre Cassigneul, chief executive officer. “Predictive’s novel approach and compelling clinical data from several multi-center clinical trials have resulted in significant adoption of the CertNDx™ Bladder Cancer Assay in the urology community. I believe the CertNDx tests have the potential to greatly improve the diagnosis and management of bladder cancer. We will be evaluating opportunities for in vitro diagnostic kit development and expansion into the primary care market. In addition to bladder cancer, there is also a need for improved management of patients with prostate cancer. This novel approach of stratifying patients is being utilized to develop CertNDx tests for prostate cancer.”
Mr. Cassigneul previously served as vice chairman of the board and president and chief executive officer of XDx Inc., a molecular diagnostics company focused on non-invasive gene expression testing. Under his leadership, XDx received Food and Drug Administration (FDA) clearance for and launched the AlloMap® Gene Expression Test for use in transplant management, representing the first U.S. molecular diagnostics company to obtain FDA approval of an in vitro diagnostic multivariate index assay (IVDMIA). Additionally, he has held top management positions at Becton Dickinson, Bayer Diagnostics, Ortho Diagnostic Systems (Johnson & Johnson) and Abbott Laboratories in the diagnostics division. He also served on the board of the Personalized Medicine Coalition.
“We thank Marc for a tremendous year of achievements during his leadership as CEO and for his continued support as COO,” said Michael A. Greeley, chairman of Predictive Biosciences’ board of directors and general partner at Flybridge Capital Partners. “We look forward to working closely with Pierre as he builds on the company’s success to date and defines the future strategic direction for Predictive. We believe he has the leadership and commercial track record that will be critical to the next phase of the company’s growth as we focus on maximizing the potential of the CertNDx product line.”
About Predictive Biosciences
Predictive Biosciences develops novel molecular diagnostic cancer assays and provides molecular pathology services for urology-based practices. Leveraging a portfolio of patented biomarkers and clinical approaches, the company has built a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. The company is backed by leading investors, including Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, New Enterprises Associates, Inc. (NEA) and ProQuest Investments. For additional information, please visit www.predictivebiosci.com.